2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 353-355
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

456 Talin 1 and calcium-and integrin-binding protein 1 (CIB1) are co-activators of platelet integrin αIIbβ3

Manjuprasanna Voddarahalli Nagaraju, PhD, Deepa Gautam, PhD2, Meghna Naik, MS3, Ulhas Naik, PhD4
1 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
2 Brigham and Women’s Hospital; Harvard Medical School, Boston, Massachusetts, United States
3 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
4 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Introduction
It is well established that binding of talin 1 to the β3 cytoplasmic tail is essential and sufficient for αIIbβ3 activation in platelets. We previously demonstrated that calcium- and integrin-binding protein 1 (CIB1) binds to the αIIb cytoplasmic tail during platelet activation. Using Cib1-/- mice, we further showed that CIB1 positively regulates in vivo thrombosis. However, the role of CIB1 in regulating platelet inside-out and/or outside-in signaling remains poorly defined.
Methods
Human platelet functional assays, such as aggregation, platelet spreading, and clot retraction, were performed to evaluate the inhibitory effects of CIB1inhibitor compounds. Flow cytometry was used to assess PAC-1 binding and P-selectin expression. Western blot analysis was performed to examine activation of signaling pathways. Immunoprecipitation and blue native gel electrophoresis were used to evaluate protein-protein interactions and protein complex formation, respectively. In vivo thrombosis studies were performed using Cib1-/- and C57BL/6J wild-type (WT) mice.
Results
Using high-throughput screening, we identified and characterized 6 small-molecule inhibitors that disrupt the interaction between CIB1 and the αIIb cytoplasmic tail. Interestingly, 2 of the 6 compounds shared an identical core structure but differed in their side-chain substitutions. The specificity of these compounds for CIB1 was evaluated using Cib1-/- mouse platelets. CIB1 inhibitors reduced WT mouse platelet aggregation and JON/A binding by approximately 60%, comparable to the reduction observed in Cib1-/- platelets. In contrast, these compounds had no effect on platelet aggregation or JON/A binding in Cib1-/- platelets, indicating that their inhibitory effects are specific to CIB1-dependent platelet activation. The compounds were next evaluated for their effects on human platelet αIIbβ3 activation. As a negative control, we used a structural analogue of one active compound that lacked inhibitory activity toward the CIB1-αIIb interaction. All 6 active compounds, but not the inactive analogue, dose-dependently (0.1–2.0 μM) inhibited thrombin-, collagen-, and ADP-induced human platelet aggregation and PAC-1 binding, with complete inhibition achieved at approximately 0.5 μM in washed human platelets. To determine whether these compounds affected platelet granule secretion, we measured P-selectin exposure. Although P-selectin expression was modestly reduced, substantial P-selectin exposure remained at concentrations that completely abolished PAC-1 binding, suggesting that α-granule secretion occurs largely independently of αIIbβ3 activation. We next examined the effects of these compounds on agonist-induced inside-out signaling. None of the 6 compounds affected intracellular Ca²⁺ mobilization, Rap1 activation, or talin 1 binding to the β3 cytoplasmic tail, indicating that they act downstream of these signaling events at the final step of αIIbβ3 activation.
To investigate the role of CIB1 in outside-in signaling, 3 active compounds and the inactive analogue were evaluated in human platelet clot retraction assays. In the presence of the active compounds, thrombin-induced clots formed normally but failed to retract, demonstrating a critical role for CIB1 in platelet outside-in signaling. Consistent with these findings, Cib1-/- mouse platelets exhibited impaired clot retraction and outside-in signaling. Furthermore, human platelets treated with CIB1 inhibitors failed to spread on immobilized fibrinogen, closely resembling the phenotype of Cib1-/- platelets, further supporting an essential role for CIB1 in outside-in signaling in both human and mouse platelets.

Conclusions
Our findings demonstrate that disruption of the CIB1-αIIb interaction by small-molecule inhibitors prevents agonist-induced αIIbβ3 activation despite intact inside-out signaling, including normal intracellular Ca²⁺ mobilization, Rap1 activation, and talin 1 binding to the β3 cytoplasmic tail. These results challenge the longstanding paradigm that talin 1 binding to the β3 tail is sufficient for αIIbβ3 activation. Instead, our data identify CIB1 as a previously unrecognized co-activator of αIIbβ3 that functions together with talin 1 to achieve full αIIbβ3 activation and efficient platelet function. These findings also establish CIB1 as a promising therapeutic target and suggest that CIB1-specific small-molecule inhibitors warrant further investigation as a novel class of antiplatelet agents.
 
Manjuprasanna Voddarahalli Nagaraju, PhD: No relevant conflicts of interest to declare.